DBV Technologies–SEVERAL: investment, 202503– financing round up to €284.5m with €116.3m upfront + up to €168.2m if full warrants exercise

	Period	2025-03-27
	Money taker	DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Stock Market: DBVT)
	Group	DBV Technologies (Group)
	Money source	SEVERAL
	Product	Viaskin® Peanut
	Product 2	investment banking
	Person	Bardon, Christiana (MPM Capital 202503 Managing Partner at MPM BioImpact)
	Source	DBV Technologies S.A.. (3/27/25). "Press Release: DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved". Châ

Record changed: 2025-03-30

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for DBV Technologies (Group)

[1] DBV Technologies S.A.. (3/27/25). "Press Release: DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved". Ch...
[2] DBV Technologies S.A.. (10/16/23). "Press Release: DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer". Montrouge....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)